<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03013543</url>
  </required_header>
  <id_info>
    <org_study_id>RM-493-014</org_study_id>
    <nct_id>NCT03013543</nct_id>
  </id_info>
  <brief_title>Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity</brief_title>
  <official_title>Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhythm Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhythm Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the effect of setmelanotide (RM-493) on weight,&#xD;
      hunger assessments and other factors in patients with rare genetic disorders of obesity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Setmelanotide on Body Weight Reduction</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of patients in each subgroup of RGDO who achieve at least 5% body weight reduction from baseline, at ~3 months treatment with setmelanotide.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pro-opiomelanocortin (POMC) Deficiency Obesity (Heterozygous or Epigenetic)</condition>
  <condition>Leptin Receptor Deficiency Obesity</condition>
  <condition>Smith-Magenis Syndrome</condition>
  <condition>Obesity Due to Melanocortin 4 Receptor Deficiency (Disorder)</condition>
  <arm_group>
    <arm_group_label>Setmelanotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Setmelanotide subcutaneous injection once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Setmelanotide</intervention_name>
    <description>RM-493 once daily subcutaneous injection</description>
    <arm_group_label>Setmelanotide</arm_group_label>
    <other_name>RM-493</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with the following genotypes and/or clinical assessment:&#xD;
&#xD;
               1. POMC/PCSK1/LEPR heterozygous - not currently enrolling new patients&#xD;
&#xD;
               2. POMC/PCSK1/LEPR compound heterozygous (two different mutations in gene) or&#xD;
                  homozygous deficiency obesity&#xD;
&#xD;
               3. POMC/PCSK1/LEPR composite heterozygous (two or more mutations in two or more&#xD;
                  genes) deficiency obesity - not currently enrolling new patients&#xD;
&#xD;
               4. Smith-Magenis Syndrome (SMS)&#xD;
&#xD;
               5. SH2B1 deficiency obesity - not currently enrolling new patients&#xD;
&#xD;
               6. Chromosomal rearrangement of the 16p11.2 locus causing obesity - not currently&#xD;
                  enrolling new patients&#xD;
&#xD;
               7. CPE compound heterozygous or homozygous deficiency obesity&#xD;
&#xD;
               8. Leptin deficiency obesity with loss of response to metreleptin&#xD;
&#xD;
               9. SRC1 deficiency obesity - not currently enrolling new patients&#xD;
&#xD;
              10. MC4R deficiency obesity - not currently enrolling new patients&#xD;
&#xD;
             Note: The specific genotype for all patients must be reviewed by the Sponsor prior to&#xD;
             study enrollment to confirm that the patient meets Inclusion Criterion #1. In&#xD;
             addition, enrollment of patients in some subgroups may be prioritized by the Sponsor&#xD;
             in order to ensure enrollment of patients with (1) well described, loss-of-function&#xD;
             genetic mutations, (2) a variety of genetic variants, or (3) genetic variants likely&#xD;
             to respond to setmelanotide.&#xD;
&#xD;
          2. Age 6 years and above.&#xD;
&#xD;
          3. Obese, defined as Body Mass Index (BMI) ≥ 30 kg/m2 for patients ≥16 years of age or&#xD;
             BMI≥ 95th percentile for age and gender for patients 6 up to 16 years of age.&#xD;
&#xD;
          4. Study participant and/or parent or guardian is able to communicate well with the&#xD;
             Investigator, to understand and comply with the requirements of the study, and is able&#xD;
             to understand and sign the written informed consent/assent.&#xD;
&#xD;
          5. Female participants of child-bearing potential must be confirmed non-pregnant, and&#xD;
             agree to use contraception as outlined in the protocol. Female participants of&#xD;
             non-childbearing potential, defined as surgically sterile (status post hysterectomy,&#xD;
             bilateral oophorectomy, or bilateral tubal ligation), post-menopausal for at least 12&#xD;
             months (and confirmed with a screening Follicle-Stimulating Hormone [FSH] level in the&#xD;
             post-menopausal lab range), and failure to have achieved menarche, do not require&#xD;
             contraception during the study.&#xD;
&#xD;
          6. Male participants with female partners of childbearing potential must agree to a&#xD;
             doublebarrier method if they become sexually active during the study. Male patients&#xD;
             must not donate sperm during and for 90 days following their participation in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recent intensive (within 2 months) diet and/or exercise regimen with or without the&#xD;
             use of weight loss agents including herbal medications that has resulted in &gt; 2%&#xD;
             weight loss.&#xD;
&#xD;
          2. Use of any medication that is approved to treat obesity within three months of first&#xD;
             dose of study drug (e.g., orlistat, lorcaserin, phentermine-topiramate,&#xD;
             naltrexone-bupropion). Note:Glucagon-like peptide-1 (GLP-1) receptor agonists may be&#xD;
             used up to the dose approved for the treatment of diabetes mellitus (e.g., liraglutide&#xD;
             up to a daily dose of 1.8 mg) as long as (1) is it not being prescribed for the&#xD;
             treatment of obesity, (2) the dose has been stable for at least three months prior to&#xD;
             enrollment, (3) the patient has not experienced weight loss during the previous three&#xD;
             months, AND (4) the patient intends to keep the dose stable throughout the course of&#xD;
             the study.&#xD;
&#xD;
          3. Gastric bypass surgery within the previous six months or any prior gastric bypass&#xD;
             surgery resulting in &gt;10% weight loss durably maintained from the baseline&#xD;
             pre-operative weight with no evidence of weight regain. Specifically, patients may be&#xD;
             considered if surgery was not successful, or resulted in &lt;10% weight loss compared to&#xD;
             pre-operative baseline weight or clear evidence of weight regain after an initial&#xD;
             response to bariatric surgery. All patients with a history of bariatric surgery must&#xD;
             be discussed with and receive approval from the Sponsor prior to enrollment.&#xD;
&#xD;
          4. Diagnosis of schizophrenia, bipolar disorder, personality disorder or other&#xD;
             psychiatric disorder(s) that the Investigator believes will interfere significantly&#xD;
             with study compliance.&#xD;
&#xD;
             Neurocognitive disorders affecting ability to consent will not be disqualifying as&#xD;
             long as an appropriate guardian able to give consent has been appointed.&#xD;
&#xD;
          5. A PHQ-9 score of ≥ 15 or any suicidal ideation of type 4 or 5 on the C-SSRS during&#xD;
             Screening, any lifetime history of a suicide attempt, or any suicidal behavior in the&#xD;
             last month. Note: Patients who are unable to complete the PHQ-9 or C-SSRS due to&#xD;
             significant neurocognitive defects may be allowed to enroll in the study, as long as&#xD;
             in the opinion of the Primary Investigator there are no clinical signs or symptoms of&#xD;
             suicidal behavior.&#xD;
&#xD;
          6. Current, clinically significant pulmonary, cardiac, or oncologic disease considered&#xD;
             severe enough to interfere with the study and/or confound the results. Any patient&#xD;
             with a potentially clinically significant disease should be reviewed with the Sponsor&#xD;
             to determine eligibility.&#xD;
&#xD;
          7. HbA1c &gt;9.0% at Screening&#xD;
&#xD;
          8. History of significant liver disease or abnormal liver tests on Screening (i.e. &gt; 1.5&#xD;
             x upper limit of normal [ULN] for alanine transaminase [ALT], aspartate transaminase&#xD;
             [AST], alkaline phosphatase, or serum bilirubin). Note: Patients entering the study&#xD;
             with SRC1 haploinsufficiency obesity must be evaluated during the Screening Period for&#xD;
             hepatic fibrosis by appropriate imaging techniques (e.g., transient elastography or&#xD;
             magnetic resonance elastography). Any patient with moderate or greater fibrosis (e.g.,&#xD;
             the equivalent of a METAVIR score ≥ 2) will be excluded from the study. Note: A&#xD;
             patient with a diagnosis of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic&#xD;
             steatohepatitis (NASH) may be allowed to enroll in the study, after consultation with&#xD;
             the Sponsor. Other significant liver disease, such as cirrhosis, are exclusionary.&#xD;
&#xD;
          9. Glomerular filtration rate (GFR) &lt;30 mL/min at Screening.&#xD;
&#xD;
         10. History or close family history (parents or siblings) of skin cancer or melanoma (not&#xD;
             including non-invasive/infiltrative basal or squamous cell lesion), or patient history&#xD;
             of ocular-cutaneous albinism.&#xD;
&#xD;
         11. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions&#xD;
             (excluding non-invasive basal or squamous cell lesion), determined as part of a&#xD;
             comprehensive skin evaluation performed by a qualified dermatologist during Screening.&#xD;
&#xD;
             Any concerning lesions identified during the Screening Period will be biopsied and&#xD;
             results known to be benign prior to enrollment. If the pre-treatment biopsy results&#xD;
             are of concern, the patient may need to be excluded from the study.&#xD;
&#xD;
         12. Patient is, in the opinion of the Study Investigator, not suitable to participate in&#xD;
             the study.&#xD;
&#xD;
         13. Participation in any clinical study with an investigational drug/device within 3&#xD;
             months prior to the first day of dosing.&#xD;
&#xD;
         14. Patients previously enrolled in a clinical study involving setmelanotide or any&#xD;
             previous exposure to setmelanotide.&#xD;
&#xD;
         15. Significant hypersensitivity to any excipient in the study drug.&#xD;
&#xD;
         16. Inability to comply with QD injection regimen.&#xD;
&#xD;
         17. Females who are breastfeeding or nursing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murray Stewart, BM/DM</last_name>
    <role>Study Chair</role>
    <affiliation>Rhythm Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Simon Williamson Clinic, PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Phoenix Southeast</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Central Arizona Medical Associates, PC</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials-Downtown</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials Headquarters</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Wake Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anschutz Health and Wellness Center University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Endocrinology and Diabetes Children's National Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AXIS South Florida Clinical Trials</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - St. Petersburg</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Partners</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIH Hatfield Clinical Research Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medicine</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Medicine for Obesity Research: Gastroenterology &amp; Hepatology Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Impact Clinical Trials</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AXIS New York Clinical Trials</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AXIS Clinical Trials</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Inc.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Akron</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obesity Institute, Geisinger Clinic</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Primary Care Associates, PC</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research TN</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Le Bonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-3157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic Research Institute</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Trousseau - Nutrition et Gastroentérologie</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de pédiatrie CHU de la Réunion - Hôpital Félix Guyon</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97405</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Río</city>
        <state>Patras</state>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edmond and Lily Safra Children's Hospital</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <zip>65 28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2017</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>POMC deficiency obesity</keyword>
  <keyword>LepR deficiency obesity</keyword>
  <keyword>Smith-Magenis Syndrome</keyword>
  <keyword>MC4R deficiency obesity</keyword>
  <keyword>SRC1 deficiency obesity</keyword>
  <keyword>SH2B1 deficiency obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smith-Magenis Syndrome</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

